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Background
HCV Triple therapy opens new perspectives for HCV
cure in HIV-HCV patients but data concerning the use
of HVC DAA-PI in this patients in a real life setting are
scarce. Our objective was to evaluate efficacy and safety of
Telaprevir (TLV) and Boceprevir ( BOC) based- therapy in
our cohort.
Materials and methods
We included HIV-HCV patients treated with Peg Inter-
feron RIB (PR) plus TLV/BOC between 2011-2013 in a
multicenter retrospective cohort. Demographic, clinical
and imunologic characteristics were obtained, as well as
adverse events and discontinuations. Treatment efficacy
and safety data were collected at week (W) 4, 8, 12, 24
and 48 . Success if HCV-RNA became undetectable
(PCRHVC-)72 weeks after the end of treatment (SVR).
Failure if treatment was discontinued due to virologic
failure (VF), adverse events (AE).
Results
31 patients were analyzed, 5 Naives and 26 re-treatments
(21% relapsers, 53% non responders and 26% intolerance
discontinuation). All were Caucasian, 86% were male
with a 49 years old’s mean age. Mode of transmission
of HIV& HCV was IUDV for 24 patients, MSM for1.
Median CD4 counts 692. All were on HAART with
undetectable Viral Load in 92%. Background HIV therapy
contained in 51% raltegravir (RAL), 20% ritonavir-
boosted atazanavir (ATV/r), 12% etravirine (ETV) 9%
darunavir (DRV/r),6% lopinavir, efavirenz and rilpivirine.
Tenofovir in 72%. Genotype 1a (n=20) or 1b (n=10) or
4 (n=1), METAVIR fibrosis stage was F3F4 in 55%, F2 in
32% and F0F1 in 13% of cases. HVC was treated with
PR + BOC (33%) or TLV (67%). 25 patients reached
W72. PCRVHC- was observed in 54% of patients at W4,
67% at W12, 58% at W24 and 58% at W48. SVR was
obtained for 58% (50% on PR+BOC, 64% on PR+TLV)
and in 51% of cirrhotic patients. Six patients discontinued
therapy for VF (n=1) or AE (n=5).
Conclusion
Despite SVR increased with DAA-PI based therapy, treat-
ment of HCV in HIV remains complex with multiple chal-
lenges, including high pill burden, higher rates of adverse
events (AEs) and difficult drug-drug-interactions.
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